| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | AG-014699 | GDSC1000 | pan-cancer | AAC | -0.043 | 0.2 |
| mRNA | GSK-650394 | GDSC1000 | pan-cancer | AAC | 0.045 | 0.2 |
| mRNA | Compound 23 citrate | CTRPv2 | pan-cancer | AAC | 0.043 | 0.2 |
| mRNA | PD-0325901 | CCLE | pan-cancer | AAC | -0.053 | 0.2 |
| mRNA | BRD-K70511574 | CTRPv2 | pan-cancer | AAC | 0.041 | 0.2 |
| mRNA | Imatinib | GDSC1000 | pan-cancer | AAC | -0.065 | 0.2 |
| mRNA | BRD-A71883111 | CTRPv2 | pan-cancer | AAC | 0.047 | 0.2 |
| mRNA | HC-067047 | CTRPv2 | pan-cancer | AAC | 0.048 | 0.2 |
| mRNA | 17-AAG | CCLE | pan-cancer | AAC | 0.058 | 0.2 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.042 | 0.2 |